NCT04040231View on ClinicalTrials.gov

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 24, 2019

Primary Completion Date

November 14, 2024

Study Completion Date

November 14, 2024

Conditions
MesotheliomaPleural MesotheliomaWilms Tumor
Interventions
BIOLOGICAL

Galinpepimut-S

Galinpepimut-S will be administered alone on weeks 0 and 2. Participants will receive the galinpepimut-S vaccine and nivolumab over 16 weeks in the initial treatment phase.

DRUG

Nivolumab

Participants will receive nivolumab and the galinpepimut-S vaccine over 16 weeks in the initial treatment phase.

BIOLOGICAL

Sargramostim

All participants will receive Sargramostim (GM-CSF) 70 mcg injected subcutaneously on days 0 and -2 of each cycle

Trial Locations (6)

10021

Memorial Sloan - Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04040231 - Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma | Biotech Hunter | Biotech Hunter